Abstract:67 Background: Previous studies indicate a preexisting T cell response and the associated “adaptive immune resistance” are critical for the clinical efficacy of anti-PD-1/PD-L1 immunotherapy. The study explored the activated IFN-γ pathway and the expression of interferon regulatory factor 1 (IRF-1), as surrogates of preexisting T cell response, as potential biomarkers associated with clinical benefit (CB) for ESCC patients receiving anti-PD-1/PD-L1 therapy. Methods: Thirty-one ESCC patients treated with PD-1/PD-L1 blockade antibody, alone or in combination, were enrolled. Tumor response evaluation was made according to Response Evaluation Criteria in Solid Tumours 1.1, and CB was defined as complete response, partial response or stable disease at least 6 months. Formalin-fixed paraffin-embedded tissues from 31 patients were analyzed for the expression of PD-L1 and IRF-1 by immunohistochemistry; 13 tissues were analyzed for the expression of immune-related genes by NanoString nCounter Human PanCancer Immune Profiling. Results: Of 31 enrolled patients (M: F= 30: 1, median age of 58), 23 and 8 were of recurrent and de novo metastatic ESCC. Sixteen and 15 received PD-1/PD-L1 blockade alone and PD-1/PD-L1-based combination therapy, respectively; 13 had received at least 2 lines of systemic therapy for advanced disease. The response rate was 10%, and the CB rate was 16%. The median progression-free-survival (PFS) and overall survival are 1.8 and 5.6 months, respectively. The 25-gene IFN-γ signature was significant higher in patients with CB than in patients without CB ( P = 0.020). Neither PD-L1 expression on tumor cells (TC) nor on immune cells (IC) was associated with CB ( P = 0.489 and 0.646, respectively). However, the IRF-1 expression on TC or on IC was significantly associated with CB ( P < 0.001 and 0.005, respectively). Conclusions: Activated IFN-γ pathway determined by 25-gene IFN-γ signature and high IHC-expression of IRF-1 were associated with CB in advanced ESCC patients receiving anti-PD-1/PD-L1-based therapy. (Supported by the grant of MOST 105-2314-B-002 -186 -MY3).

Involvement of ERK and JNK Pathways in IFN-γ-induced B7-DC Expression on Tumor Cells

Dual role of interferons in tumor immunology

IL-6/ERK signaling pathway participates in type I IFN-programmed, unconventional M2-like macrophage polarization

Interferon Gamma Inhibits CXCL8-Induced Proliferation and Migration of Pancreatic Cancer BxPC-3 Cell Line Via a RhoGDI2/Rac1/NF-κB Signaling Pathway.

Dysregulation in IFN-γ signaling and response: the barricade to tumor immunotherapy

Critical Role of Dendritic Cell-Derived Il-27 in Antitumor Immunity Through Regulating the Recruitment and Activation of Nk and Nkt Cells

Type I IFN signaling on dendritic cells is required for NK cell-mediated anti-tumor immunity

B7DC/PDL2 Promotes Tumor Immunity by a PD-1–independent Mechanism

Single-cell transcriptomic sequencing analysis of mechanistic insights into the IFN-γ signaling pathway in different tumor cells

The Involvement Of Tnf-Alpha-Related Apoptosis-Inducing Ligand In The Enhanced Cytotoxicity Of Ifn-Beta-Stimulated Human Dendritic Cells To Tumor Cells

Functional Expression of B7H1 on Pancreatic Carcinoma Panc-1 Cells

Activated Interferon-Γ (Ifn-Γ) Pathway Associated with Clinical Benefit to Programmed Cell Death Protein-1 (PD-1)/PD Ligand 1 (Pd-L1)-based Therapy in Esophageal Squamous Cell Carcinoma (ESCC).

The Involvement of TNF-α-Related Apoptosis-Inducing Ligand in the Enhanced Cytotoxicity of IFN-β-Stimulated Human Dendritic Cells to Tumor Cells

Interferon-γ in the tumor microenvironment promotes the expression of B7H4 in colorectal cancer cells, thereby inhibiting cytotoxic T cells

Intratumoral injection of interferon-gamma gene-modified dendritic cells elicits potent antitumor effects: effective induction of tumor-specific CD8 + CTL response

Type I IFN Activating Type I Dendritic Cells for Antitumor Immunity

cGAS-STING pathway mediates activation of dendritic cell sensing of immunogenic tumors

Role of PD‐1 in modulating IFN‐γ‐CXCL9/10‐CXCR3 signaling in breast cancer

Interaction of B7-H1 on Intrahepatic Cholangiocarcinoma Cells with Pd-1 on Tumor-Infiltrating T Cells As A Mechanism of Immune Evasion

Opposing Effects of Interferon-Alpha and Interferon-Gamma on the Expression of Major Histocompatibility Complex Class I Chain-Related A in Tumors.

ER-localized JmjC domain-containing protein JMJD8 targets STING to promote immune evasion and tumor growth in breast cancer